An SH2-domain-containing kinase negatively regulates the phosphatidylinositol-3 kinase pathway

被引:26
|
作者
Moniakis, J
Funamoto, S
Fukuzawa, M
Meisenhelder, J
Araki, T
Abe, T
Meili, R
Hunter, T
Williams, J
Firtel, RA [1 ]
机构
[1] Univ Calif San Diego, Sect Cell & Dev Biol, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Ctr Genet Mol, La Jolla, CA 92093 USA
[3] Univ Dundee, Sch Biol Sci, Wellcome Trust Labs, Dundee DD1 5EH, Scotland
[4] Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA
关键词
Dictyostelium; PI3K; SH2; domain; kinase; Akt/PKB;
D O I
10.1101/gad.871001
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
SHK1 is a novel dual-specificity kinase that contains an SH2 domain in its C-terminal region. We demonstrate that SHK1 is required for proper chemotaxis and phagocytosis. Mutant shk1 null cells lack polarity, move very slowly, and exhibit an elevated and temporally extended chemoattractant-mediated activation of the kinase Akt/PKB. GFP fusions of the PH domain of Akt/PKB or the PH-domain-containing protein CRAC, which become transiently associated with the plasma membrane after a global stimulation with a chemoattractant, remain associated with the plasma membrane for an extended period of time in shk1 null cells. These results suggest that SHK1 is a negative regulator of the PI3K (phosphatidylinositol-3 kinase) pathway. Furthermore, when a chemoattractant gradient is applied to a wild-type cell, these PH-domain-containing proteins and the F-actin-binding protein coronin localize to its leading edge, but in an shk1 null cell they become randomly associated with the plasma membrane and cortex, irrespective of the direction of the chemoattractant gradient, suggesting that SHK1 is required for the proper spatiotemporal control of F-actin levels in chemotaxing cells. Consistent with such functions, SHK1 is localized at the plasma membrane/ cortex, and we show that its SH2 domain is required for this localization and the proper function of SHK1.
引用
收藏
页码:687 / 698
页数:12
相关论文
共 50 条
  • [1] The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion
    Wu, X
    Obata, T
    Khan, Q
    Highshaw, RA
    White, RD
    Sweeney, C
    BJU INTERNATIONAL, 2004, 93 (01) : 143 - 150
  • [2] The phosphatidylinositol-3 kinase/mTOR pathway: new agents
    CL Arteaga
    Breast Cancer Research, 13
  • [3] Clinical Development of Phosphatidylinositol-3 Kinase Pathway Inhibitors
    Arteaga, Carlos L.
    PHOSPHOINOSITIDE 3-KINASE IN HEALTH AND DISEASE, VOL 2, 2011, 347 : 189 - 208
  • [4] Phosphatidylinositol-3 kinase activity in B cells is negatively regulated by Lyn tyrosine kinase
    Xu, Yuekang
    Huntington, Nicholas D.
    Harder, Kenneth W.
    Nandurkar, Harshal
    Hibbs, Margaret L.
    Tarlinton, David M.
    IMMUNOLOGY AND CELL BIOLOGY, 2012, 90 (09): : 903 - 911
  • [5] The phosphatidylinositol-3 kinase/mTOR pathway: new agents
    Arteaga, C. L.
    BREAST CANCER RESEARCH, 2011, 13
  • [6] Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma
    Aziz, Saadia A.
    Jilaveanu, Lucia B.
    Zito, Christopher
    Camp, Robert L.
    Rimm, David L.
    Conrad, Patricia
    Kluger, Harriet M.
    CLINICAL CANCER RESEARCH, 2010, 16 (24) : 6029 - 6039
  • [7] Genetic Alterations in the Phosphatidylinositol-3 Kinase/Akt Pathway in Thyroid Cancer
    Xing, Mingzhao
    THYROID, 2010, 20 (07) : 697 - 706
  • [8] The Phosphatidylinositol 3-Kinase/Akt Pathway Negatively Regulates Nod2-Mediated NF-kappaB Pathway
    Zhao, Ling
    Lee, Joo Y.
    Hwang, Daniel H.
    FASEB JOURNAL, 2008, 22
  • [9] The phosphatidylinositol 3-kinase/Akt pathway negatively regulates Nod2-mediated NF-κB pathway
    Zhao, Ling
    Lee, Joo Y.
    Hwang, Daniel H.
    BIOCHEMICAL PHARMACOLOGY, 2008, 75 (07) : 1515 - 1525
  • [10] PHOSPHATIDYLINOSITOL-3 KINASE AND GROWTH-REGULATION
    SOLTOFF, SP
    CARPENTER, CL
    AUGER, KR
    KAPELLER, R
    SCHAFFHAUSEN, B
    CANTLEY, LC
    COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1992, 57 : 75 - 80